Concord Biotech’s IPO to open on 4th August, 2023

The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.

Jemperli plus chemotherapy approved in the US as the first new frontline treatment option for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy

Biogen to acquire Reata Pharmaceuticals

Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth

Upsurge in pink eye conjunctivitis cases in the country

Take proper precautions and seek timely treatment!

Biocon Foundation releases 2nd edition of consensus guidelines for head & neck cancer

Marks the World Head & Neck Cancer Day at the OCTF Conference

Syngene Q1 FY 2024 revenue up 26% to Rs. 832 crores, PAT up 26% to Rs.93 Cr

Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24

ABDM supports the integration of digital health infrastructure

Health-tech startups have the potential to revolutionize the healthcare sector by supporting innovations

Biocon Biologics gets EMA’s positive opinion for an ophthalmology product

Lonza delivers 5.6% CER sales growth and 30% CORE EBITDA margin

Good momentum in commercial CDMO business

Glenmark Life Sciences reports robust 25% EBITDA growth in Q1FY24

The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.